- Home
- ARVN vs NVCT Comparison
ARVN vs NVCT Comparison
Compare ARVN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | NVCT |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 617.7M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARVN | NVCT |
|---|---|---|
| Price | $6.82 | $18.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | $13.93 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 772.6K | 183.0K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.80 | $5.55 |
| 52 Week High | $14.22 | $29.28 |
Technical Indicators
Market Signals| Indicator | ARVN | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 28.59 | 36.38 |
| Support Level | N/A | $17.98 |
| Resistance Level | $8.52 | $22.84 |
| Average True Range (ATR) | 0.30 | 1.41 |
| MACD | -0.03 | -0.30 |
| Stochastic Oscillator | 8.61 | 9.43 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.